Francis Crick Institute

Mass spectrometry is a powerful method and enables the parallel measurement of hundreds of proteins and metabolites from a few microlitres of blood from COVID-19 patients. We use this technology to develop prognostic assays and tests. These predict at early stages of the disease, its future progression, and identifies the individuals at risk for worsening. Further, we use these technologies to monitor the success of clinical trials and vaccine developments and help to identify new powerful targets for the development of therapies.